Comphya, a clinical-stage medtech innovator from Lausanne, Switzerland, has secured CHF 7.5 million in an oversubscribed Series A funding round. The company focuses on addressing erectile dysfunction (ED), particularly in patients unresponsive to conventional oral treatments. The influx of funds aims to expand their breakthrough neurostimulation device, CaverSTIM, designed to improve the lives of men recovering from prostate surgery. With the new capital, Comphya plans the execution of pivotally important clinical trials in both the United States and Australia, promising hope for those affected by treatment-induced erectile issues.
Past endeavors have highlighted Comphya’s commitment to advancing ED treatments. Initial studies in Australia have yielded promising results, confirming CaverSTIM as a viable alternative to current methods, with patients successfully maintaining erectile function post-surgery. Although Comphya’s recent advancements mark the first U.S. pilot, the company remains steadfast in its international collaboration and patient-focused innovation since its inception.
What is Comphya’s CaverSTIM?
CaverSTIM represents Comphya’s flagship solution for post-prostatectomy erectile dysfunction. Unlike traditional therapies, such as invasive injections or implants, CaverSTIM offers a minimally invasive approach. This implantable neurostimulator aims to address the needs of patients unresponsive to oral medications through innovative neurostimulation techniques.
Designed to be implanted in the pelvic cavity, the CaverSTIM’s system targets the restoration of penile nerve function. An external clinician controller enables precise and individual adjustments, underscoring its adaptability to various patient needs. This cutting-edge system aligns with Comphya’s objective to advance neurostimulation for those unable to benefit from standard pharmacological interventions.
How is the Funding Utilized?
Comphya plans to allocate the recently raised funds to initiate a U.S. pilot study at Johns Hopkins. Further validation from the FDA’s Investigational Device Exemption has paved the way for advancing critical research stages scheduled throughout 2026. Extensive clinical trials contribute to solidifying the device’s safety, efficacy, and regulatory readiness for broader clinical application.
Additionally, Comphya aims to intensify its Australian trials to gather comprehensive safety and efficacy data. The funds will enhance their ability to recruit a broader patient base and solidify CaverSTIM’s utility further. This aligns with enhancing global clinical research for innovations targeting surgical and post-treatment complications.
“We are thrilled to have the continued confidence of our investors,” commented Pim van Wesel, CEO of Comphya. “These resources enable us to take decisive steps toward accelerating our mission,” he added.
Comphya’s strategic focus has evolved under new leadership. Since appointing Pim van Wesel as CEO in 2025, the company has entered a critical growth phase, underpinning its strategic initiatives with a robust leadership vision. This strategic transformation emphasizes Comphya’s commitment to refining treatment options for ED patients post-surgery.
The broader scope of Comphya’s research initiatives highlights the evolving landscape of medical interventions for erectile dysfunction. The progression from foundational research to actionable clinical trials demonstrates a sustained effort to address treatment gaps. By investing in comprehensive testing and regulatory approvals, Comphya reinforces its dedication to advancing safe, effective solutions for a previously underserved patient demographic.
